Litcius/Paper detail

Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial

Mazen Noureddin, Shaharyar M. Khan, Francisco R. Portell, Diane K. Jorkasky, Jameel Dennis, Omer Khan, L. E. B. Johansson, Edvin Johansson, Arun J. Sanyal

2023˜The œLancet. Gastroenterology & hepatology39 citationsDOI

Topics & Concepts

MedicinePlaceboFatty liverInternal medicineClinical endpointRandomized controlled trialPlacebo-controlled studyGastroenterologySurgeryDouble blindDiseasePathologyAlternative medicineLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationDiabetes, Cardiovascular Risks, and Lipoproteins
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial | Litcius